'Nothing can be done' in genetic Fragile X Syndrome a myth

Image
IANS Kolkata
Last Updated : Feb 18 2017 | 3:57 PM IST

The absence of clinical medicine to treat Fragile X Syndrome, the most common known genetic cause of autism, does not mean it is not amenable to other forms of care, say experts debunking myths about the inherited condition.

"For something that is not treatable by medicine, you tend to think nothing can be done. The doctor's job is to get somebody better. The real myth is there is no chemical medicine so nothing can be done," Samir Dalwai, Indian Academy of Paediatrics, Mumbai chapter, told IANS.

Fragile X Syndrome (FXS) is the most common cause of inherited intellectual disability and the most common known genetic cause of autism or autism spectrum disorders.

Approximately 1 in 3,000 to 4,000 individuals has FXS. It causes a range of developmental problems including learning disabilities and cognitive impairment.

Usually, males are more severely affected by this disorder than females.

The awareness level in India with respect to other countries is considerably low, says Shalini Kedia, chairperson, Fragile X Society of India.

"It is necessary for spreading awareness about the syndrome among the medical fraternity especially paediatricians and gynaecologists as well as parents and couples planning to have a child, so that children with Fragile X Syndrome are detected early in life," Kedia told IANS.

There is no medication that has a benefit specifically for fragile X syndrome. Drugs are commonly used to treat symptoms of attention deficit and hyperactivity, anxiety, and aggression and so, supportive management becomes necessary.

Kedia said in developed countries like the US, toddlers at the age of 36-42 months are detected with Fragile X Syndrome whereas, in India, children with Fragile X Syndrome are detected at a later age of 6-8 years or even later. This leads to a huge gap in their treatment cycle.

Dalwai hoped guidelines on FXS would soon be available.

"We have a chapter of neurodevelopmental paediatrics and we just came out with guidelines on autism, ADHD. We would be very happy to come out with guidelines on FXS. Once we have looked at autism, after that next thing should be to look at specific causes of autism and intellectual disability," he added.

--IANS

sgh/ksk/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 18 2017 | 3:44 PM IST

Next Story